Navigation Links
Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
Date:11/11/2013

rials. Further information about the company can be found at www.orexigen.com.

Orexigen Forward‐Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: the potential for, and timing of, the approval of a Contrave Marketing Authorization Application (MAA) in the European Union (EU); the probability of the interim analysis of the Light Study excluding a prespecified level of risk of MACE; the potential for, and timing of, resubmission of a NDA for Contrave based on interim results of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the safety and effectiveness of Contrave; the potential for, and timing of, the accrual and adjudication of MACE in the Light Study; the probability of overall success of the Light Study; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the potential for the FDA to continue to honor the Special Protocol Assessment, or SPA; the potential to enter into a collaborative partnership for commercialization of Contrave outside of North America; the potential for Takeda to commercially launch Contrave in North America; and the use of pharmacotherapy to treat obesity. The inclusion of forward‐looking statements should not be regarded as a representation by Or
'/>"/>

SOURCE Orexigen Therapeutics, Inc.; Takeda Pharmaceuticals, U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Kalorama Information says that ... to be robust; the market is driven by ... global markets, new product innovations and increasing life ... market inhibitors, such as government restraints, limited hospital ... The healthcare market research publisher,s report, Insulin ...
(Date:4/20/2015)... , April 20, 2015  Published results ... trends in the ability of Neuraltus Pharmaceuticals ... of amyotrophic lateral sclerosis (ALS, also known as ... treatment period. While NP001,s slowing of decline in ... was not statistically significant, clinically meaningful slowing of ...
(Date:4/20/2015)... ADDISON, Texas , April 20, 2015 /PRNewswire/ ... have entered a settlement agreement with Inter-Mountain Capital ... with a warrant exercise. Under ... 361,516 shares of Common Stock, issued an unsecured ... Warrant to purchase 194,118 shares of Common Stock ...
Breaking Medicine Technology:Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5ULURU Inc. Announces the Settlement of Outstanding Litigation 2
... ANGELES, Jan. 5, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical, ... Golden Globe Awards introducing new products and giving away freebies ... include its flagship weight loss product, PhenTabz as part of ... celebrities at the upcoming Golden Globe awards in the GBK ...
... /PRNewswire-iReach/ -- FutureNet,s Ambulatory Electronic Health Record ... stamp of approval by earning ONC-ATCB certification. The ... of enabling ambulatory/outpatient providers to qualify for funding ... Tested and certified under the Drummond Group,s Electronic ...
Cached Medicine Technology:Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 3
(Date:4/21/2015)... On Saturday, May 2nd, 2015, board ... his team from Georgia Eye Physicians and Surgeons ... Now, being held in Piedmont Park by the Lupus ... be the largest LFA-sponsored walk in the nation, hosting ... funds and awareness for lupus, an unpredictable and potentially ...
(Date:4/21/2015)... “The warm summer season is fast approaching,” says Marta ... younger than her age? In the ongoing battle against ... Signs of premature aging are deep wrinkles and unsightly ... spent in the sun without adequate protection.” , Outward appearances ... dangers of UV rays can go deep below the surface. ...
(Date:4/20/2015)... (PRWEB) April 21, 2015 Using Quality ... CMOs Speed Production and Improve Compliance , **FDAnews Webinar**, ... EDT, http://www.fdanews.com/qualitybydesign , The life sciences industries ... them to do more with less. Mergers, acquisitions, ... CMOs to finds ways to speed up production while ...
(Date:4/20/2015)... City, NY (PRWEB) April 21, 2015 ... as a 2015 Professional Woman of the Year. Ms. ... in healthcare. As the largest, most-recognized networking organization of ... and profession, the National Association of Professional Women is ... and over 200 local chapters. , “We are like ...
(Date:4/20/2015)... 20, 2015 The NFL draft season is ... players to add to their rosters, both for their skills ... this episode of SCI TV , Vinnie Iyer ... of Greg Hardy given increased attention on off-field conduct in ... after the Ray Rice scandal brought media scrutiny, once again, ...
Breaking Medicine News(10 mins):Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:National Association of Professional Women Announces Suzanne Webb, Chief Executive Officer at Exclusive Surgeries Network, LLC, a 2015 Professional Woman of the Year 2Health News:Character Concerns in the NFL with Vinnie Iyer on SCI TV 2
... surveillance is an acceptable alternative to surgical excision in ... without cell abnormalities, a new study shows. , The ... Pacific Medical Center in San Francisco, included 119 papillomas ... follow-up of a minimum of two years without surgical ...
... 2 (HealthDay News) -- Aspirin is just as effective as ... failure patients with a normal heart rhythm, a landmark ... researchers from Columbia University in New York City said their ... because it is much cheaper. The 10-year study was ...
... the University of California, Davis, are among 12 scientists ... Hartwell Foundation this year. The awards provide $100,000 of ... well as videoconferencing equipment for periodic communications with the ... funding a UC Davis Hartwell Foundation postdoctoral researcher with ...
... West Orange, NJ. May 2, 2012. Kessler Foundation will be ... on Cognition in Multiple Sclerosis to be held at the ... 2012. John DeLuca, PhD, the Foundation,s VP of Research and ... Strober, PhD, and James Sumowski, PhD. Kessler Foundation ...
... - The University of Texas MD Anderson Cancer Center President ... of Sciences (NAS) - one of the most prestigious accolades ... and engineering. DePinho is the first member of the ... The NAS is a private, nonprofit society of distinguished ...
... NY(May 1, 2012) Large majorities of older Americans ... according to a new national survey, "How Does It ... by the John A. Hartford Foundation, a champion for ... Institute for Geriatric Nursing at New York University,s College ...
Cached Medicine News:Health News:Surgical excision unnecessary in some patients with benign papillomas 2Health News:Aspirin as Effective as Warfarin for Heart Failure: Study 2Health News:Biomedical researchers receive Hartwell Foundation awards 2Health News:Biomedical researchers receive Hartwell Foundation awards 3Health News:UT MD Anderson President Ronald DePinho elected to National Academy of Sciences 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: